Emerging evidence suggests that 1.25(OH)2D3 may impede the mammalian target of rapamycin (mTOR) signaling pathway by upregulating DNA damage-inducible transcript 4 (DDIT4) (Yang et al., 2015; Wang et al., 2016), presenting potential avenues for halting DKD progression. This evidence concerns the gene MTOR and diabetic kidney disease.